You are here

Article Text

Article menu
Download PDFPDF
Letter
SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study
  1. Arthur Mageau1,2,3,4,
  2. Geoffrey Aldebert5,
  3. Damien Van Gysel4,6,
  4. Thomas Papo1,2,4,
  5. Jean-François Timsit3,4,7,
  6. Karim Sacre1,2,4
  1. 1 Médecine Interne, Hôpital Bichat, AP-HP, Paris, France
  2. 2 Centre de Recherche sur l'Inflammation, Laboratoire d'Excellence Inflamex, INSERM UMR 1149, CNRS ERL8252, Paris, France
  3. 3 Infection, Antimicrobials, Modeling, Evolution (IAME), INSERM UMR 1137, Paris, France
  4. 4 Faculté de Médecine site Bichat, Université de Paris, Paris, France
  5. 5 Etalab, French task force for Open Data, Paris, France
  6. 6 Département d'Information Médicale, Hôpital Bichat, AP-HP, Paris, France
  7. 7 Réanimation Médicale et Infectieuse, Hôpital Bichat, AP-HP, Paris, France
  1. Correspondence to Dr Arthur Mageau, Service de Médecine Interne, Hôpital Bichat-Claude Bernard, APHP, Paris, France; arthur.mageau{at}inserm.fr

https://doi.org/10.1136/annrheumdis-2021-220010

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Since the global emergence of SARS-CoV-2 at the end of 2019, a special concern has raised regarding patients with rheumatic and inflammatory diseases, such as systemic lupus erythematosus (SLE).1 Indeed, many treated patients with SLE are immunocompromised and often suffer from chronic kidney or cardiovascular diseases.2 Recently, anti-interferon antibodies have been implicated in severe SARS-CoV-2 infection3 while it has been known for decades that patients with SLE may produce such autoantibodies.4 Although available data from short SLE series are reassuring,5 6 large-scale nationwide studies are still needed to assess the risk of developing severe SARS-CoV-2 infection in SLE.

    We therefore used the French healthcare database system called ‘Programme de Médicalisation des Systèmes d’Information’—which contains hospitalisation data of all inpatients in France—to analyse the population with SLE that had at least one stay in a French hospital between March and 30 October 2020 (online supplemental material). On this population, we compared inpatients with SLE with or without SARS-CoV-2 infection (SLE/COVID-19+, SLE/COVID-19−). Among SLE/COVID-19+ inpatients, we distinguished patients with poor outcome after SARS-CoV-2 …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors AM designed and conducted the analysis and wrote the manuscript. GA, DvG and TP were involved in the project development and edited the manuscript. KS and J-FT directed the project and wrote the manuscript.

    • Funding PhD fellowship support for AM was provided by Agence Nationale pour la recherche (no: ANR-19-CE17-0029).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.